GPH101

gene manipulation concept

First Patient Dosed With Graphite Bio’s Gene-Editing Therapy for SCD

Graphite Bio announced the dosing of the first patient with GPH101, now known as nulabeglogene autogedtemcel (nula-cel), in their phase 1/2 CEDAR trial for patients with sickle cell disease (SCD). The announcement, reported by news release, noted that the therapy is designed to definitively cure the disease by correcting the causative genetic mutation in SCD.…

Next post in SCD News Briefs